Optimizing Clinical and Economic Outcomes in the Management of Primary Immunodeficiency Diseases: Taking a Closer Look at the Role of Immunoglobulin Replacement Therapy

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from CSL Behring

Primary immunodeficiency diseases (PIDD) are a group of more than 300 rare, chronic disorders in which part of the body’s immune system is missing or functions improperly. While not contagious, these diseases are caused by hereditary or genetic defects, and, although some disorders present at birth or in early childhood, the disorders can affect anyone, regardless of age or gender. Some affect a single part of the immune system; others may affect one or more components of the system. And while the diseases may differ, they all share one common feature: each results from a defect in one of the functions of the body's normal immune system. Fortunately for patients with primary immunodeficiency disorders, the treatment paradigm has exploded in the past 10 years, giving medical directors and clinicians many more options in managing the PIDD patient population. The primary treatment for these patients with antibody deficiencies is lifetime administration of immunoglobulin replacement therapy; a therapeutic substance derived from human blood plasma and made up of immunoglobulin. These therapies have shown improved efficacy and safety for patients with PIDDs. Since Ig only replaces the missing end product but does not correct the patient’s defect in antibody production, Ig replacement is usually necessary for the patient’s lifetime. Although approximately 150,000 patients are likely to benefit from Ig replacement, only an estimated 35,000 to 55,000 receive ongoing therapy. A lack of awareness and depth of understanding contribute to this underserved population of individuals with PI thus it’s imperative healthcare professionals who manage PIDD patient populations have a solid understanding of differing options to optimize both costs and patient outcomes in their therapeutic application.

Upon completion of this activity, participants will be able to:

  • Identify patients who may have a primary immunodeficiency disease (PIDD) and discuss appropriate tests to diagnose the disease

  • Examine the mechanisms of action, efficacy, and safety profiles of current and emerging immunoglobulin (Ig) replacement therapies and strategies for their use in managing PIDD

  • Assess how the severity of comorbidities or the frequency of recurrent infections influences outcomes in patients with PIDD

  • Explore how certain management approaches such as site of care mandates, increase member cost-share, and step-therapy requirements adversely impact adherence and outcomes in PIDD

  • Analyze the total cost of care for PIDD, including direct costs associated with drug therapy and associated infections from non-treatment, as well as indirect costs

  • Apply methods to enable optimal cost management of Ig replacement therapies to be realized by multiple PIDD stakeholders including managed care organizations

Faculty: Mark Ballow, MD
Professor of Pediatrics
Pediatrics, Division of Allergy and Immunology
University of South Florida


Dr. Ballow serves on an advisory board for CSL Behring, Grifols and Shire. He also serves on the speaker's bureau for Shire. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from CSL Behring

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue